Valneva (VALN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $219.6M

Market Cap: $532.0MFounded: 2013Employees: >650HQ: Vienna, Austria

Sector Ranking#123 in Biologics / Biosimilars

Overview

Valneva is a specialty vaccine company with a mission to address unmet medical needs in infectious disease prevention. It has successfully commercialized three vaccines, including the world's first single-shot chikungunya vaccine, and is advancing a late-stage pipeline highlighted by a Lyme disease vaccine candidate developed with Pfizer. The company's strategy is built on an integrated business model, a focus on niche or neglected diseases, and strategic partnerships to maximize the value of its assets.

Infectious DiseasesTravel Health

Technology Platform

Modality-agnostic expertise in developing inactivated, live-attenuated, and protein-subunit vaccines, supported by integrated in-house manufacturing capabilities.

Funding History

4

Total raised:$219.6M

PIPE$107MUndisclosedMay 15, 2021

Grant$2.6MCEPIMar 15, 2020

Series D$110MBpifranceJun 15, 2018

IPOUndisclosedUndisclosedSep 15, 2013

Opportunities

Valneva's lead Lyme disease vaccine candidate, VLA15, addresses a massive unmet need with no current vaccine on the market, representing a multi-billion dollar commercial opportunity.

Furthermore, as the first-mover with IXCHIQ in chikungunya, the company can capture significant market share in endemic and travel markets, with potential for inclusion in national immunization programs.

Risk Factors

The company faces significant clinical and regulatory risks for its pipeline candidates, particularly the Shigella and Zika programs.

Commercial execution risk is high for both IXCHIQ and VLA15, requiring successful market adoption, pricing, and reimbursement.

Financial sustainability depends on the successful launch of these key assets.

Competitive Landscape

Valneva competes in niche segments to avoid direct competition with large vaccine giants. In Lyme disease, it faces future potential competition from earlier-stage programs (e.g., Moderna's mRNA candidate). In chikungunya, it currently has a first-mover advantage with no other approved vaccines, though several are in development.